title: Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience.
abstract: OBJECTIVE
  To ascertain whether vinblastine, bleomycin, and methotrexate (VBM) (CT) combined with extended-field radiotherapy (EF RT) is effective enough to spare laparotomy in early, favorably presenting Hodgkin's disease (HD) patients.
  
  
  METHODS
  Fifty patients with clinical stage IA or IIA HD with favorable histology and no bulky masses entered a prospective multicenter study started in January 1988. The median follow-up time was 38 months.
  
  
  RESULTS
  All patients achieved a complete remission (CR). Five relapsed after 3 to 40 months and underwent successful salvage therapy. The actuarial remission rate was 0.89% at 3 years and 0.82% at 5 years. Two patients died in CR: one of severe pulmonary toxicity, the other of a second neoplasia (adenocarcinoma of the lung), 2 and 43 months after the end of therapy, respectively. The hematologic toxicity recorded during VBM CT was mild on the whole. Major toxicity was represented by pulmonary side effects and neurologic symptoms. Multiple regression analysis demonstrated that pulmonary toxicity was significantly related only to the amount of RT delivered to the mediastinum and not to the relative dose of bleomycin, to the dose-intensities of the three drugs in the regimen, or to patient age or sex. The same statistical technique showed that the only clinical factor related to grade of neurotoxicity was vinblastine dosage.
  
  
  CONCLUSIONS
  VBM CT combined with EF RT is an effective treatment for early, clinically staged, favorable HD patients. However, the toxicity of this combination suggests that certain modifications should be evaluated.
authors.affiliation: Università di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico S. Matteo, Italy.
authors.forename: P G
authors.initials: PG
authors.lastname: Gobbi
authors.forename: C
authors.initials: C
authors.lastname: Pieresca
authors.forename: A
authors.initials: A
authors.lastname: Frassoldati
authors.forename: M
authors.initials: M
authors.lastname: Carotenuto
authors.forename: N
authors.initials: N
authors.lastname: Di Renzo
authors.forename: A
authors.initials: A
authors.lastname: La Sala
authors.forename: R
authors.initials: R
authors.lastname: Berté
authors.forename: P
authors.initials: P
authors.lastname: Avanzini
authors.forename: M
authors.initials: M
authors.lastname: Federico
authors.forename: V
authors.initials: V
authors.lastname: Silingardi
authors.forename: E
authors.initials: E
authors.lastname: Ascari
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011446:Prospective Studies; D016879:Salvage Therapy; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D008727:Methotrexate